A novel RNAi drug treats hemophilia in fewer doses Qfitlia, an RNAi therapeutic given every two months, is the first to target the antithrombin protein instead of missing clotting factors in the blood.

https://www.drugdiscoverynews.com/a-novel-rnai-drug-treats-hemophilia-in-fewer-doses-16578